Vannucchi AM, Guglielmelli P, Tefferi A. Advances in Understanding and management of myeloproliferative neoplasms. Cancer J Clin. 2009;59(3):171–91.

Article  Google Scholar 

Arber DA, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood J Am Soc Hematol. 2022;140(11):1200–28.

CAS  Google Scholar 

Khoury JD et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia, vol. 36, no. 7, pp. 1703–1719, 2022.

Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia Vera in the E uropean U Nion. Eur J Haematol. 2014;92(4):289–97.

Article  PubMed  Google Scholar 

Tefferi A, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, The Journal of the American Society of Hematology. 2014;124(16):2507–13.

CAS  Google Scholar 

Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):801–21.

Article  CAS  PubMed  Google Scholar 

Kröger N, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2024;11(1):e62–74.

Article  PubMed  Google Scholar 

Rampal R et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms, Proceedings of the National Academy of Sciences, vol. 111, no. 50, pp. E5401-E5410, 2014.

Baxter EJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61.

Article  CAS  PubMed  Google Scholar 

Levine RL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97.

Article  CAS  PubMed  Google Scholar 

Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–90.

Article  CAS  PubMed  Google Scholar 

James C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol. 434, no. 7037, pp. 1144–1148, 2005.

Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86(8):668–76.

Article  CAS  PubMed  Google Scholar 

Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Hematology. 2014;2014(1):268–76.

Article  PubMed  Google Scholar 

Klampfl T, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90. https://doi.org/10.1056/NEJMoa1311347.

Article  CAS  PubMed  Google Scholar 

Nangalia J, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.

Article  PubMed  PubMed Central  Google Scholar 

Pardanani AD et al. MPL 515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol. 108, no. 10, pp. 3472–3476, 2006.

Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J. Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythemia. J Mol Diagn. 2017;19(1):92–8.

Article  CAS  PubMed  Google Scholar 

McGaffin G, Harper K, Stirling D, McLintock L. JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol, 167, 2, 2014.

Thompson ER et al. Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing, Haematologica, vol. 106, no. 1, p. 313, 2020.

Tefferi A, Vannucchi AM. Genetic risk assessment in myeloproliferative neoplasms, in Mayo Clinic Proceedings, 2017, vol. 92, no. 8: Elsevier, pp. 1283–1290.

Tefferi A, et al. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018;93(3):348–55.

Article  CAS  PubMed  Google Scholar 

Gangat N, Reichard KK, Orazi A, Viswanatha DS, Hanson CA, Tefferi A. Treatment-relevant misdiagnosis of autoimmune myelofibrosis. Haematologica, 2020.

Tefferi A et al. Essential thrombocythemia: A review, Jama, 2025.

Alvarez-Larrán A, et al. Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. Ann Hematol. 2019;98(10):2319–28.

Article  PubMed  Google Scholar 

Milosevic Feenstra JD, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood J Am Soc Hematol. 2016;127(3):325–32.

CAS  Google Scholar 

Cabagnols X, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127(3):333–42.

Article  CAS  PubMed  Google Scholar 

Swierczek S, Lima LT, Tashi T, Kim SJ, Gregg XT, Prchal JT. Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia. 2015;29(12):2432–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forte D, et al. Distinct profile of CD34 + cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease. Journal of Experimental & Clinical Cancer Research. 2021;40(1):49.

Alimam S, et al. Patients with triple-negative, JAK2 V617F-and CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Adv. 2021;5(4):1059–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guglielmelli P, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2017;36(4):310–8.

Article  PubMed  Google Scholar 

Tefferi A, et al. MIPSS70 + Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. Journal of Clinical Oncology. 2018;36(17):1769.

Article  PubMed  Google Scholar 

Tefferi A et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons, Leukemia, vol. 28, no. 7, pp. 1472–1477, 2014.

Rotunno G, et al. Mutational landscape of patients with myelofibrosis that do not harbor mutations in JAK2, MPL and Calreticulin driver genes. Blood. 2015;126(23):4091.

Article  Google Scholar 

Al-Ghamdi YA, et al. Triple-negative primary myelofibrosis: a bone marrow pathology group study. Mod Pathol. 2023;36(3):100016.

Article  CAS  PubMed  Google Scholar 

Coltro G, et al. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood advances. 2020;4(15):3677–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Svidnicki MCCM et al. Mutations in triple-negative patients with myeloproliferative neoplasms, Blood, vol. 134, p. 5395, 2019.

Cattaneo D, et al. Triple-negative essential thrombocythemia: clinical-pathological and molecular features. A single-center cohort study. Front Oncol. 2021;11:637116.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Acha P et al. Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms. Am J Hematol, 94, 10, pp. E264-E267, 2019.

Crespiatico I et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis, Blood, vol. 143, no. 14, pp. 1399–1413, 2024.

Tefferi A, et al. TP53 mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance. American journal of hematology. 2025;100(4):552–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tefferi A, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hautin M, Mornet C, Chauveau A, Bernard DG, Corcos L, Lippert E. Splicing anomalies in myeloproliferative neoplasms: paving the way for new therapeutic venues. Cancers. 2020;12(8):2216.

Article